Navigation Links
Kaiser Permanente Joins With Top Health Care Groups to Create Healthier Hospital Environments
Date:10/18/2007

Oakland Event Kicks Off Sector-Wide Initiative

OAKLAND, Calif., Oct. 18 /PRNewswire/ -- Kaiser Permanente, a leader in green building and environmentally responsible purchasing, has partnered with a group of influential health care organizations to help spread green practices across the industry.

As a founding member of the Global Health and Safety Initiative, Kaiser Permanente aims to share best practices and help to broaden the market for cleaner energy, safer products and innovative environmental technologies.

"If we collaborate, we can create leverage in the marketplace for safer and healthier practices that protect patients and staff while reducing our overall environmental footprint," said George C. Halvorson, chairman and CEO of Kaiser Foundation Health Plan, Inc., and Kaiser Foundation Hospitals. "Our hope is that through the Global Health and Safety Initiative, many more leaders in the health care sector will realize that being green is a team sport."

Health care is one of the largest and fastest growing sectors of the economy, representing more than 15 percent of the nation's gross national product. Health care facilities in the United States generate 2 million tons of waste per year that pose occupational and environmental threats. In addition, health care accounts for 11 percent of all commercial energy use in America and is a major water consumer.

Kaiser Permanente has broad experience with green building, environmentally responsible purchasing and sustainable operations. Over the past five years, for example, Kaiser Permanente has chosen ecologically sustainable materials for 29 million square feet in new construction, prevented the release of 70 billion pounds of air pollutants annually and saved more than $10 million per year through energy conservation strategies.

Global Health and Safety Initiative partners include the nonprofit groups Health Care Without Harm, the Center for Health Design, and
'/>"/>

SOURCE Kaiser Permanente
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Rat joins list of cloned animals
3. Richard Gere Joins Indian Stars For Fight Against AIDS
4. Enbrel Joins with Methotrexate to Cure Rheumatoid Arthritis
5. Anoushka Joins Hands With WFP to Feed the Poor
6. India Joins Hands With Global Body for Vaccine Research
7. Another Statewide Organization Joins the Fight Against Assisted Suicide
8. Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius
9. Poor health care in Russia maybe causing Decline in its Population
10. Startling Expose – Physicians Often Have No Regular Source Of Health Car
11. Debate Rages over firing of HIV infected health care workers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...uncement Available, RADNOR, Pa., May 16 /PRNewswi...al Health Month and Older Pennsylvanians Month, Fe...ffer an important message to senior,citizens throu...ce,announcement developed by Feeling Blue SPC is i...oblem of depression and to offer hope to older,Pen...
(Date:5/16/2008)...Tao Formulations announces the,official launch of ...ernal,Medicine 2008 conference in Washington DC. T...ars of research to develop a safe, all-natural,no...ng menopausal symptoms., Company founder and CEO,... gynecologist, founded Tao Formulations (http://w...
(Date:5/16/2008)...h Type 2 Diabetes and High LDL- ...ly Added to ACE/AACE Road Maps, PARSIPPANY, N.J.,...,announced today that data from two pooled analyse...m HCl), in combination with metformin- or,sulfonyl...ucose (as,measured by A1C) in patients with type 2...
(Date:5/16/2008)...dergoing mastectomy (total breast removal) for ear...hree years at Mayo Clinic in Rochester. The increa... years. , Researchers say the reasons for this i... women at Mayo Clinic who underwent diagnostic mag...treat early-stage breast cancer had a higher rate ...
Breaking Medicine News(10 mins):Health News:Suicide Prevention Group Delivers Much-Needed Message to Pennsylvania's Elderly 2Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 3Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 4Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 5Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 6Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 7Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 2Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 3
...ing research that suggests high doses of vitamin E...ost prevalent diseases in the world with many rava... Complications can lead to heart disease, eye dama...ll over the body and can also cause complications ...
...seems to be the latest mantra of Pfizer. The phar... free antifungal drug to 50 countries hardest hit ...s close on the heels of the South African Governme... companies. In an announcement on Wednesday Pfize...
...at Rao Matapurkar, from Maulana Azad Medical Colle...ing the first patent on organ regeneration from th...essfully regenerating / repairing organs in human ...tent office granted him a patent on this technique...
...ng up and taking in the aroma of Indian cuisine. T... are now the subjects of research by scientists at... Dr. Daniel Y. C. Fung and colleagues who conducte...he air with its spicy aroma can also double up as ...
Other Medicine News:
(Date:5/15/2008)... Data from Prostate, Colorectal and Ovarian ...old Investor Event on Sun., June 1 with Oncology E...Newswire-FirstCall/ -- Poniard,Pharmaceuticals, In...ocused,on oncology, today announced that the Compa... picoplatin, in various tumor types and combinatio...
(Date:5/15/2008)... research reflects depth and breadth of, collabor...treatments for diverse form...t of Zometa(R), the leading IV, bisphosphonate, on...cancer, - Four oral sessions to feature RAD001, f..., including first results of RECORD-1 study in ren...
(Date:5/15/2008)...- Sanofi-aventis,(EURONEXT:...from the,landmark ATHENA study showed Multaq(R) (d... of patients with atrial fibrillation or atrial fl...alizations or death from any,cause by a statistica...udy,primary endpoint. The ATHENA results will be p...
(Date:5/15/2008)... 15 /- Ergonex Pharma today,announced...on (FDA) has,granted orphan drug designation to Te...pertension (PAH). Terguride is currently being eva...pe., "The FDA,s grant of orphan drug designation ...r development program by offering regulatory,clin...
Breaking Medicine Technology:Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Bullying threatens nurses health and careers 14828 1Cato Study Finds Iran a Surprising Model for Kidney Markets 14823 1Cato Study Finds Iran a Surprising Model for Kidney Markets 14823 2Tiny buckyballs squeeze hydrogen like giant Jupiter 2561 1Tiny buckyballs squeeze hydrogen like giant Jupiter 2561 2Methamphetamine Use Associated With Pulmonary Arterial Hypertension in Patients With Previously Unknown Risk Factors 14819 1Methamphetamine Use Associated With Pulmonary Arterial Hypertension in Patients With Previously Unknown Risk Factors 14819 2Methamphetamine Use Associated With Pulmonary Arterial Hypertension in Patients With Previously Unknown Risk Factors 14819 3
...ws nearly nine out of ten patients taking,once-dai...onths, WASHINGTON, D.C., May 22, 2007 /PRNewswire-...-14 month extension study (303),presented at the B...n Glasgow, Scotland in March 2007 showed Shire plc... moderate UC,patients. Today, secondary endpoints ...
...g-term Response at Stable Doses, According to,New ...LANTA, May 22, 2007 /PRNewswire/ -- UCB announced ... Week 2007 (DDW),demonstrated long-term response a...ith Cimzia (certolizumab pegol), the only Fc-free,...lled PRECiSE 3 (P3), is a long-term open label,con...
Other Medicine Technology:Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8UCB Presents Long-Term CImzia Data in Crohn's Disease 2UCB Presents Long-Term CImzia Data in Crohn's Disease 3UCB Presents Long-Term CImzia Data in Crohn's Disease 4UCB Presents Long-Term CImzia Data in Crohn's Disease 5
Facial Mask
Facial Chin and Neck Support
Abdominal Binder w / Velcro
CDIs Abdominal Binders are designed with a non-pitching, body contouring, non-rolling elastic band that provides both support and compression. Available in 9, 12 and 15 widths with waist ranges from
Medicine Products: